Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Monoclonal antibody Hu3F8 receives FDA orphan drug status for osteosarcoma

Jan. 14, 2014

EMA accepts Biovest's MAA for BiovaxID

Jan. 14, 2014

GlaxoSmithKline presents a novel antibody-drug conjugate for the treatment of multiple myeloma

Jan. 13, 2014

Researchers present phase I results for 225Ac-lintuzumab in older patients with AML

Jan. 13, 2014

IGN-532 shows preclinical efficacy in xenograft models of AML

Jan. 10, 2014

Galena enrolls first patient in phase II trial of GALE-301 cancer immunotherapy in ovarian cancer

Jan. 9, 2014

Development of a novel ROR1 peptide-based cancer vaccine

Jan. 9, 2014

Committee recommends stopping Imbruvica study based on significant survival improvement

Jan. 8, 2014

Generex Biotechnology confirms database lock for AE-37 breast cancer vaccine trial

Jan. 8, 2014

Vaccination with ImMucin leads to promising clinical response in phase I/II trials

Jan. 8, 2014

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...